Approval · Notice of Compliance 6011 · 2004
HYDROMORPH.IR: Notice of Compliance 6011
Issued December 24, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 6011
- Date
- December 24, 2004
- Company
- Purdue PharmaToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Admin
- Reason
- Product name change from palladone.ir
- Therapeutic class
- Opioid analgesic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| HYDROMORPH.IR | 02245703 | Cancelled Post Market |
| HYDROMORPH.IR | 02245704 | Cancelled Post Market |
| HYDROMORPH.IR | 02245705 | Cancelled Post Market |
Medicinal ingredients
- HYDROMORPHONE HCL 2 MG per TAB
- HYDROMORPHONE HCL 4 MG per TAB
- HYDROMORPHONE HCL 8 MG per TAB